To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Platelet-Rich Plasma vs. Placebo for Achilles Tendon Rupture: 2 Year Outcomes

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
January 2023

Platelet-Rich Plasma vs. Placebo for Achilles Tendon Rupture: 2 Year Outcomes

Vol: 303| Issue: 1| Number:12| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Platelet-rich plasma injection for acute Achilles tendon rupture : two-year follow-up of the PATH-2 randomized, placebo-controlled, superiority trial

Bone Joint J. 2022 Nov;104-B(11):1256-1265.

Contributing Authors:
DJ Keene J Alsousou P Harrison HM O'Connor S Wagland SJ Dutton P Hulley SE Lamb K Willett PATH-2 Trial Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

182/230 patients from the PATH-2 trial responded to this 2-year follow-up study of the PATH-2 trial comparing platelet-rich plasma (PRP; n=88/114) and placebo (92/116). The outcomes of interest included the Achilles Tendon Rupture Score (ATRS), the Patient-Specific Functional Scale (PSFS), and the Short-Form 12 (SF-12) mental and physical component quality of life scores. The results of this study...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue